Here's a clear breakdown of Vanda Pharmaceuticals' DEF 14A proxy statement, explaining what it means for investors:

📄 What This Document Is

• This is the Definitive Proxy Statement (DEF 14A) for Vanda Pharmaceuticals' 2026 Annual Meeting of Stockholders.
• It details the proposals stockholders will vote on and provides essential background information.
• Why it matters: It's your guide to understanding what decisions shareholders need to make and the company's performance and governance.

🏢 What The Company Does

• In simple terms: Vanda is a biopharmaceutical company focused on developing and commercializing therapies primarily for central nervous system (CNS) disorders.
• Key Products: They sell Fanapt® (schizophrenia), HETLIOZ® (Non-24 disorder), and PONVORY® (multiple sclerosis).
• Pipeline: They have several drugs in development, including long-acting injectables for schizophrenia, treatments for motion sickness (NEREUS™), psoriasis, ulcerative colitis, depression, and social anxiety disorder.

💰 Financial Highlights (2025 Full Year)

• Total Revenues: $216.1 million.
  • Fanapt® Net Sales: $117.3 million
  • HETLIOZ® Net Sales: $71.4 million
  • PONVORY® Net Sales: $27.4 million
• Net Loss: $220.5 million. Crucially, this includes a non-cash charge of $113.7 million for a valuation allowance against deferred tax assets.
• Cash Position: $263.8 million in cash, equivalents, and marketable securities at year-end. This is a significant resource for a biotech company.

🚀 Key Business & Pipeline Moves (2025-2026)

• NEREUS™ (motion sickness): FDA approved in Dec 2025.
• HETLIOZ® (jet lag): FDA rejected the application (Jan 2026). Vanda requested a formal public hearing, which the FDA granted (Mar 2026).
• PONVORY®: Started Phase III trials for psoriasis and ulcerative colitis.
• Fanapt®: Ongoing Phase III trial for a long-acting injectable in schizophrenia relapse prevention. Also testing it for treatment-resistant hypertension.
• BYSANTI™ (MDD): Began enrolling patients in a Phase III adjunctive treatment trial.
• Imsidolimab (GPP): Submitted a Biologics License Application (BLA) to the FDA (Q4 2025).
• VQW-765 (Social Anxiety): Started a Phase III study (Q4 2025).
• License Deal: Signed an exclusive global license with AnaptysBio for imsidolimab (Jan 2025).

🗳️ What You're Voting On (Proposals)

1. Elect Directors (FOR Each): Vote to elect Richard W. Dugan, Charles C. Duncan, Ph.D., and Anne Sempowski Ward as Class II directors (term until 2029).
2. Ratify Auditor (FOR): Approve PricewaterhouseCoopers LLP as the independent auditor for 2026.
3. Approve Executive Pay (Say-on-Pay) (FOR): Advisory vote approving compensation for named executive officers. Last year ~74% approved.
4. Amend Equity Plan (FOR): Increase the number of shares available for issuance under the 2016 Equity Incentive Plan to attract/retain talent.

⚖️ Corporate Governance & Executive Pay Highlights

• Board: 7 directors (6 independent). Over 66% refreshment since 2019. 2 women directors (29% diversity). Average tenure ~11.2 years. Lead Independent Director (Richard Dugan).
• Pay Practices:
  • Annual bonuses tied to objective company goals (revenue, clinical milestones, filings) - no guaranteed payouts.
  • Strong Stock Ownership Guidelines (CEO: 6x salary; others: 3x salary; Directors: 3x retainer).
  • Clawback Policy for incentive compensation.
  • No "Single-Trigger" change-of-control benefits (need termination after change).
  • No Pensions/Enhanced Benefits beyond standard plans.
  • Anti-Hedging & Anti-Pledging Policy.
• Shareholder Friendly: No "evergreen" plan increases, no option repricing without shareholder approval, expired poison pill (Apr 2025), majority voting standard for directors.

🔮 What's Next

• FDA Decisions: Awaiting outcome of HETLIOZ® jet lag public hearing and imsidolimab BLA review.
• Clinical Trials: Key Phase III readouts expected for Fanapt® LAI (schizophrenia), PONVORY® (psoriasis/UC), BYSANTI™ (MDD), VQW-765 (social anxiety).
• Commercial Launch: Supporting NEREUS™ launch for motion sickness.
• Capital: Utilizing the $263.8M cash position to fund operations and pipeline advancement.

⚖️ Big Picture: Strengths & Risks

• 👍 Strengths:
  • Diversified marketed product portfolio generating revenue.
  • Significant cash reserves ($263.8M).
  • Active and broad pipeline across multiple therapeutic areas.
  • Strong corporate governance practices.
  • Recent FDA approval (NEREUS™).
• ⚠️ Risks:
  • Significant net loss ($220.5M in 2025).
  • Regulatory setbacks (HETLIOZ® jet lag rejection).
  • Pipeline execution risk (clinical trial failures/delays).
  • Commercialization risk for new products (NEREUS™, future launches).
  • Reliance on key products (Fanapt®, HETLIOZ®, PONVORY®) for revenue.
  • Ongoing need for capital despite current cash position.

🧠 The Analogy

Think of Vanda like a ship captain (management/board) navigating through potentially stormy seas (regulatory decisions, clinical trials) with a reasonably stocked hold (cash) and a diverse set of fishing nets cast (pipeline) in hopes of catching new supplies (approvals/sales). The annual meeting is the crew (shareholders) reviewing the captain's plan, performance, and key officers before deciding whether to keep the course.

🧩 Final Takeaway

Vanda is a well-governed biotech with current revenue streams and a substantial cash cushion, but facing significant challenges from a major net loss (driven partly by a non-cash tax charge) and a key FDA setback on jet lag. Shareholders are voting on leadership, oversight, pay, and equity plans while the company advances multiple late-stage trials across its pipeline aiming for future growth.